Most Recent
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
Sportsbet has won the dismissal of a trade mark lawsuit brought by a Melbourne-based snake handler who goes by the name of "snakeman" over an ad by the online bookmaker featuring an incompetent snake charmer.
A US sports news website founded by former Yankees shortstop Derek Jeter featuring content by athletes has filed a lawsuit alleging an Australian sports site has violated its IP.
Take-Two interactive has won an injunction blocking a Grand Theft Auto gamer from distributing software that allows users to access restricted features of the popular game, a month after reaching a settlement with a gamer in a separate copyright case.
BMW Australia plans to challenge the NSW Supreme Court's power to create a common fund order spanning six class actions brought against major players in the automotive industry over defective and dangerous Takata air bags.
On the eve of a hearing into damages, rival pavement engineering companies have resolved a copyright dispute that continued important law on what constitutes infringement of computer software source code.
Six major car companies indicated Tuesday they were open to a quick settlement of class actions brought on behalf of potentially hundreds of thousands of Australian drivers whose cars were fitted with defective and deadly Takata airbags.
The Full Federal Court has shot down Reckitt Benckiser's appeal of a ruling that it misled consumers with claims that its Nurofen is a more effective pain killer than rival GlaxoSmithKline's Panadol.
A Federal Court judge skipped vital witness testimony when he ruled Reckitt Benckiser misled consumers about the effectiveness of its Nurofen painkiller, the pharmaceutical company told the Full Federal Court Monday.
The final day of trial in the ACCC's case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as 'onerous' a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant 'inherited' from Novartis.